Quick answer: Growth hormone secretion does decline measurably with age in most adults, a well-documented pattern sometimes called somatopause, with the steepest fall in the size and frequency of nighttime pulses. Published estimates commonly describe a decline on the order of a mid-single-digit percentage per year after early adulthood, though individual variation is wide and the figures depend heavily on measurement method. Declining growth hormone is a normal physiological change rather than a disease. Lower levels on their own do not mean any treatment is warranted, and that determination belongs to a licensed clinician.
Growth hormone decline is one of the few claims in this space that is not oversold. Secretion peaks in adolescence and early adulthood and falls steadily afterward, and the pattern has been observed consistently enough that endocrinology textbooks treat it as ordinary physiology. Where the claim gets stretched is the leap from a real decline to the conclusion that everyone experiencing it needs something done about it.
What actually declines, and how it is measured
Growth hormone does not simply drain away at a constant rate; the pattern of release changes. Adults secrete growth hormone in bursts rather than continuously, and what falls with age is mainly the amplitude and frequency of those bursts, most noticeably the large one that normally arrives soon after sleep onset. Losing pulse amplitude is a different phenomenon from a flat drop in a background level.
Measurement is the reason published figures disagree with each other. A single random growth hormone blood draw tells you almost nothing, because you may have sampled a peak or a trough, so research relies on frequent sampling over many hours or on stimulation testing. Numbers quoted for annual decline depend heavily on which of those methods produced them.
IGF-1 is the practical workaround in clinical settings. Insulin-like growth factor 1 is produced by the liver in response to growth hormone and is stable in the bloodstream in a way growth hormone is not, reflecting roughly the preceding day rather than the preceding minute. Clinicians use IGF-1 as a safety and context marker interpreted against an age-appropriate reference range, not as a score to drive upward.
Why sleep and decline are entangled
Sleep and growth hormone decline are difficult to separate cleanly. The largest natural pulse occurs during deep slow wave sleep, and slow wave sleep itself decreases with age, so a portion of the hormonal decline travels alongside a change in sleep architecture. Untangling cause from consequence in that pair has not been fully accomplished in humans.
Practical consequences follow from the entanglement. Fragmented sleep, late alcohol, and untreated sleep apnea all blunt the same nighttime window, which means some of what a man attributes to age is downstream of habits and undiagnosed conditions. Our piece on why sleep is where people notice something first covers that window in more detail.
Is somatopause a diagnosis?
Somatopause is a descriptive term, not a diagnosis, and the distinction carries real weight. Adult growth hormone deficiency is a recognized clinical condition with defined diagnostic criteria, typically arising from pituitary disease, surgery, radiation, or injury, and it is diagnosed with stimulation testing rather than a single lab value. Age-related decline in an otherwise healthy adult is a different situation entirely.
Conflating the two is the most common piece of dishonesty in peptide marketing. A man in his forties with an IGF-1 in the lower part of an age-appropriate range does not thereby have a deficiency, and treating a normal reading as pathology is how people get sold things they do not need. Any clinician worth using will make that distinction out loud.
What decline does and does not explain
Growth hormone decline is genuinely associated with changes men in their forties tend to report, including shifts in body composition, slower recovery from training, and lighter sleep. Association, however, is doing a lot of work in that sentence, because aging changes testosterone, muscle mass, mitochondrial function, sleep, stress load, and activity level all at once. Attributing a specific symptom to one hormone is rarely defensible.
Symptoms that look hormonal frequently are not. Fragmented sleep and low drive can reflect untreated sleep apnea, thyroid disease, depression, anemia, or a medication side effect, and each of those has a real workup. A clinician who orders that workup before reaching for peptide therapy is being careful rather than obstructive.
Restoration is the honest ceiling to describe here. Nothing available returns an adult to the hormonal profile of a twenty-five-year-old, and any provider implying otherwise has told you something useful about themselves. Our comparison of sermorelin and synthetic HGH covers why the two approaches to the same axis are not interchangeable.
Frequently Asked Questions
At what age does growth hormone start to decline?
Growth hormone secretion peaks around adolescence and begins falling in early adulthood, with the decline continuing steadily from there. Most men notice associated changes considerably later than the decline actually starts. Individual variation in both timing and rate is wide.
Is low growth hormone in an older adult a medical problem?
Age-related decline in growth hormone is considered normal physiology rather than disease. Adult growth hormone deficiency is a separate, recognized condition usually arising from pituitary damage and requiring formal stimulation testing to identify. Only a clinician can determine which situation applies to you.
Can you raise growth hormone naturally?
Sleep, resistance training, and body composition all influence growth hormone secretion, and protecting deep sleep is the most direct lever available to most people. Effects of lifestyle measures are modest and none of them reverse aging physiology. Anyone who has already done these things consistently and still feels off is in a different conversation than someone who has not.
Should I get my growth hormone tested?
Testing growth hormone directly is rarely informative outside a clinical protocol, because levels pulse and a random draw reflects timing more than status. Clinicians generally look at IGF-1 instead, interpreted against an age-appropriate range alongside your history and symptoms. Whether testing is warranted at all is a clinical judgment.
Does declining growth hormone mean I should start peptide therapy?
Declining growth hormone by itself does not indicate treatment, and a lab value below the middle of a reference range is not a prescription. Eligibility is determined by a licensed clinician through intake review, medical history, medications, and appropriate labs, and certain histories such as active or recent malignancy rule it out entirely. A prescription is not guaranteed.
The honest summary
Growth hormone decline with age is real, well documented, and unremarkable. Pulse amplitude falls, the nighttime burst shrinks, IGF-1 drifts down, and the pattern holds across populations. Believing the decline is easy; the harder question is what, if anything, it justifies doing.
Normal is the key word. Age-related decline is not a deficiency, a low-normal lab is not a diagnosis, and the symptoms men attribute to it often have other explanations that deserve ruling out first. Compounded sermorelin is not FDA-approved, is prescribed only when a licensed clinician judges it appropriate after evaluation, and belongs in a conversation about restoration rather than one about turning back a clock.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Growth hormone secretion in the elderly: ageing and the somatopause. Bailliere's clinical endocrinology and metabolism. 1997. PMID 9403121.
Growth Hormone and Aging. Endocrinology and metabolism clinics of North America. 2023. PMID 36948778.
Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000. PMID 10938176.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of internal medicine. 2007. PMID 17227934.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.